Compare ASTRAZENECA PHARMA with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs BIOCON - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA BIOCON ASTRAZENECA PHARMA/
BIOCON
 
P/E (TTM) x 88.7 25.8 344.2% View Chart
P/BV x 26.9 2.9 923.0% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   BIOCON
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
BIOCON
Mar-19
ASTRAZENECA PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,278707 180.7%   
Low Rs883554 159.4%   
Sales per share (Unadj.) Rs228.491.9 248.5%  
Earnings per share (Unadj.) Rs10.416.7 62.0%  
Cash flow per share (Unadj.) Rs16.324.2 67.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs98.8101.6 97.2%  
Shares outstanding (eoy) m25.00600.00 4.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.76.9 68.9%   
Avg P/E ratio x104.237.7 276.2%  
P/CF ratio (eoy) x66.426.1 254.7%  
Price / Book Value ratio x10.96.2 176.3%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m27,008378,330 7.1%   
No. of employees `0001.46.1 22.1%   
Total wages/salary Rs m1,53511,653 13.2%   
Avg. sales/employee Rs Th4,210.98,994.3 46.8%   
Avg. wages/employee Rs Th1,132.21,900.7 59.6%   
Avg. net profit/employee Rs Th191.11,635.3 11.7%   
INCOME DATA
Net Sales Rs m5,71055,144 10.4%  
Other income Rs m1231,444 8.5%   
Total revenues Rs m5,83356,588 10.3%   
Gross profit Rs m46315,883 2.9%  
Depreciation Rs m1474,478 3.3%   
Interest Rs m0709 0.0%   
Profit before tax Rs m43812,140 3.6%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,123 8.4%   
Profit after tax Rs m25910,026 2.6%  
Gross profit margin %8.128.8 28.1%  
Effective tax rate %40.817.5 233.6%   
Net profit margin %4.518.2 25.0%  
BALANCE SHEET DATA
Current assets Rs m3,20948,228 6.7%   
Current liabilities Rs m2,07030,376 6.8%   
Net working cap to sales %20.032.4 61.7%  
Current ratio x1.61.6 97.7%  
Inventory Days Days7268 105.9%  
Debtors Days Days3586 40.8%  
Net fixed assets Rs m79064,130 1.2%   
Share capital Rs m503,000 1.7%   
"Free" reserves Rs m2,41957,980 4.2%   
Net worth Rs m2,46960,980 4.0%   
Long term debt Rs m015,766 0.0%   
Total assets Rs m4,605121,924 3.8%  
Interest coverage xNM18.1-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.5 274.1%   
Return on assets %5.68.8 63.9%  
Return on equity %10.516.4 63.8%  
Return on capital %17.716.8 105.9%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m30015,506 1.9%   
Fx outflow Rs m2,01510,399 19.4%   
Net fx Rs m-1,7155,107 -33.6%   
CASH FLOW
From Operations Rs m8811,546 0.8%  
From Investments Rs m-94-7,138 1.3%  
From Financial Activity Rs mNA-2,417 0.0%  
Net Cashflow Rs m-62,103 -0.3%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 0.3 8.4 3.6%  
FIIs % 15.7 10.7 146.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.9 45.7%  
Shareholders   12,856 109,995 11.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ELDER PHARMA  FDC LTD.  PFIZER  UNICHEM LAB  ORCHID PHARMA LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Over 200 Points Down; Realty and Auto Stocks Under Pressure(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.2% while the Hang Seng is down 0.9%.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 27, 2020 10:57 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS